文献速递肝病

肝静脉压力梯度、无创检测与晚期脂肪性肝病亚型的预后

Hepatic Venous Pressure Gradient, Noninvasive Tests, and Prognosis Across the Subtypes of Advanced Steatotic Liver Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-06-11

多中心纳入696例代偿期晚期慢性肝病(脂肪性肝病各亚型),60%存在临床显著门脉高压,中位随访3.8年。调整疾病严重度后,各亚型失代偿和肝病死亡无差异;ANTICIPATE-NASH模型在各亚型中准确诊断临床显著门脉高压并独立预测失代偿。

要点

  • 各脂肪性肝病亚型调整后失代偿和肝病死亡风险相似。
  • 临床显著门脉高压独立预测所有亚型的失代偿。
  • ANTICIPATE-NASH概率≥60%可 rule-in 临床显著门脉高压并预测失代偿。

核心结论

  • 酒精相关肝病和混合型肝病粗失代偿率较高反映就诊时肝病更重,调整疾病严重度后各亚型结局相当。
  • ANTICIPATE-NASH模型在各亚型中准确识别临床显著门脉高压,侵入性和无创门脉高压指标均预测失代偿和肝病死亡。

研究设计与样本

  • 共696例,酒精相关肝病22%,代谢功能障碍相关且酒精相关肝病20%,代谢功能障碍相关脂肪性肝病58%;94%为Child-Pugh A,60%有临床显著门脉高压。
  • 主要结局为首次肝失代偿和肝病相关死亡,中位随访3.8年。

主要发现

  • 随访期间170例失代偿,137例死亡(58%肝病相关)。
  • 3年累积失代偿发生率:酒精相关肝病26%,混合型21%,代谢功能障碍相关脂肪性肝病15%;调整年龄、性别、MELD、白蛋白和肝静脉压力梯度后差异不再显著。
  • 调整模型中肝病相关死亡在各亚型间无差异。
  • 临床显著门脉高压独立预测所有亚型失代偿。
  • ANTICIPATE-NASH模型诊断临床显著门脉高压的AUC为0.831-0.894,各亚型可比。

关键数值与推荐

  • ANTICIPATE-NASH概率≥60%用于 rule-in 临床显著门脉高压。
  • ANTICIPATE-NASH诊断临床显著门脉高压AUC 0.831-0.894。
  • ANTICIPATE-NASH概率≥60%预测失代偿的调整亚分布风险比2.57-2.71。

临床怎么用

  • 对脂肪性肝病合并代偿期晚期慢性肝病患者,应评估临床显著门脉高压以分层失代偿风险。
  • ANTICIPATE-NASH模型可跨亚型用于无创识别临床显著门脉高压,概率≥60%时可 rule-in 并提示失代偿风险增高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Steatotic liver disease encompasses metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and a mixed type (metabolic dysfunction-associated and alcohol-related liver disease). We investigated the course of compensated advanced chronic liver disease across steatotic liver disease subtypes, the impact of clinically significant portal hypertension, and the role of noninvasive tests. METHODS: This study included patients with steatotic liver disease and compensated advanced chronic liver disease from 17 centers undergoing hepatic venous pressure gradient and noninvasive test assessment through December 2023. Primary outcomes were first hepatic decompensation and liver-related mortality. RESULTS: Among 696 patients (alcohol-related liver disease, 22%; metabolic dysfunction-associated and alcohol-related liver disease, 20%; metabolic dysfunction-associated steatotic liver disease, 58%), 94% had Child-Pugh A, and 60% had clinically significant portal hypertension. Over a median follow-up of 3.8 years, 170 patients decompensated, and 137 died (58% liver-related). The 3-year cumulative decompensation incidence was highest in alcohol-related liver disease (26%), followed by metabolic dysfunction-associated and alcohol-related liver disease (21%) and metabolic dysfunction-associated steatotic liver disease (15%); yet differences were no longer significant after adjusting for age, sex, Model for End-stage Liver Disease, albumin, and hepatic venous pressure gradient. Similarly, liver-related mortality did not differ by steatotic liver disease subtype in adjusted models. Clinically significant portal hypertension independently predicted decompensation across all subtypes. The ANTICIPATE-NASH model showed high and comparable diagnostic accuracy for clinically significant portal hypertension across alcohol-related liver disease, metabolic dysfunction-associated and alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease (area under the receiver operating characteristic curve = 0.831-0.894). An ANTICIPATE-NASH probability ≥60% for ruling-in clinically significant portal hypertension outperformed the original ANTICIPATE model in all subtypes and independently predicted decompensation with similar effect sizes (adjusted subdistribution hazard ratio, 2.57-2.71). CONCLUSIONS: Higher crude decompensation rates in alcohol-related liver disease and metabolic dysfunction-associated and alcohol-related liver disease reflect more severe liver disease at presentation, yet outcomes are comparable across the steatotic liver disease spectrum after accounting for disease severity. ANTICIPATE-NASH accurately identifies clinically significant portal hypertension across steatotic liver disease subtypes, and both invasive and noninvasive measures of portal hypertension predict decompensation and liver-related death.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hofer BS, Shalaby S, Kwanten W, et al. Hepatic Venous Pressure Gradient, Noninvasive Tests, and Prognosis Across the Subtypes of Advanced Steatotic Liver Disease. Clin Gastroenterol Hepatol. 2026. PMID: 42276315. doi:10.1016/j.cgh.2026.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。